Listing Thumbnail

    Anticoagulation Therapy Outcomes

     Info
    Deployed on AWS
    This data package is about anticoagulant therapy. It includes following datasets: patients with and without hematoma enlargement, chronic care management differences and patient outcomes in anticoagulant clinics, participant characteristics anticoagulants randomized trial, pulmonary embolism thrombolysis treatment and its complications.

    Overview

    Overview

    This data package is a collection of numerous studies related to anticoagulation therapy. The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed a study on behalf of IGNITE (Initiative of German Neuro-intensive Trial Engagement). The study investigated the association of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and the effects of OAC resumption. Another study compared outcome for patients using two different mode of reversal treatments: (1) Fresh Frozen Plasma (FFP), and (2) Prothrombin Complex Concentrates (PCC). A research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy. The data were subjected to regression analysis to identify to what extent the differences in patient outcomes are associated with chronic care management activities. Another study was performed to identify the differences in patient outcomes and their relationship with chronic care management of oral anticoagulant. The goal of another study was to perform a systematic review of the literature and determine pre-specified inclusion criteria based on relevant studies, which are as follows: randomized controlled design in patients with PE evaluating thrombolytic therapy as an intervention; a comparator group that included any of the following agents: low-molecular-weight heparin (LMWH), vitamin K antagonist, fondaparinux, or unfractionated heparin; and reporting of mortality outcomes. We did not include trials that compared different thrombolytic agents against one another or different doses of the same thrombolytic drug.


    License Information

    The use of John Snow Labs datasets is free for personal and research purposes. For commercial use please subscribe to the Data Library  on AWS. The subscription will allow you to use all John Snow Labs datasets and data packages for commercial purposes.


    Metadata

    DescriptionValue
    Data Package ComplexitySimple
    Available EnrichmentsN/A
    KeywordsAnticoagulant Therapy, Hematoma Treatment, Novel Anticoagulants, Chronic Care Model, Chronic Disease Management, Wagner Chronic Care Model, Thrombolytics, Treatment of Pulmonary Embolism, Warfarin Monitoring, Clotting Factors
    Other TitlesPatients on Anticoagulant Therapy With and Without Hematoma Enlargement, Chronic Care Anticoagulant Therapy Management, Warfarin Dosage in Anticoagulant Chronic Care Management, Chronic Disease Management and Patient Outcomes, Thrombolysis Treatment for Pulmonary Embolism Complications

    Included Datasets

    1. Characteristics of OAC Patients With and Without Hematoma Enlargement

    The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed this study on behalf of IGNITE (Initiative of German Neuro Intensive Trial Engagement) and was published by The Journal of the American Medical Association (JAMA) on February 24, 2015. The study investigated the association of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and the effects of OAC resumption.

    1. Chronic Care Management Differences in Anticoagulant Clinics

    This research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy. The data were subjected to regression analysis to identify to what extent the differences in patient outcomes are associated with chronic care management activities.

    1. Chronic Care Management Patient Outcomes in Anticoagulant Regions

    This research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy (OAT). This study was performed to identify the differences in patient outcomes and their relationship with chronic care management of OAT.

    1. Participant Characteristics Anticoagulants Randomized Trial JAMA

    This clinical investigation that was published in The Journal of the American Medical Association (JAMA) on June 18, 2014, was a collaboration of efforts from PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science, and CINAHL since its inception from April 10, 2014.

    1. Pulmonary Embolism Thrombolysis Treatment and Its Complications JAMA

    This clinical investigation that was published in The Journal of the American Medical Association (JAMA) on June 18, 2014, was a collaboration of efforts from PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science, and CINAHL since its inception from April 10, 2014. The goal of the study was to determine the risks and complications involved with thrombolytic therapy compared with anticoagulation in acute pulmonary embolism.

    1. Subgroup Analysis for Mode of Reversal Treatment FFP vs PCC

    The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed this study on behalf of IGNITE (Initiative of German Neuro Intensive Trial Engagement) and was published by The Journal of the American Medical Association (JAMA) on February 24, 2015. The study compared outcome for patients using two different mode of reversal treatments: (1) Fresh Frozen Plasma (FFP), and (2) Prothrombin Complex Concentrates (PCC).


    Data Engineering Overview

    We deliver high-quality data

    • Each dataset goes through 3 levels of quality review
      • 2 Manual reviews are done by domain experts
      • Then, an automated set of 60+ validations enforces every datum matches metadata & defined constraints
    • Data is normalized into one unified type system
      • All dates, unites, codes, currencies look the same
      • All null values are normalized to the same value
      • All dataset and field names are SQL and Hive compliant
    • Data and Metadata
      • Data is available in both CSV and Apache Parquet format, optimized for high read performance on distributed Hadoop, Spark & MPP clusters
      • Metadata is provided in the open Frictionless Data standard, and its every field is normalized & validated
    • Data Updates
      • Data updates support replace-on-update: outdated foreign keys are deprecated, not deleted

    Our data is curated and enriched by domain experts

    Each dataset is manually curated by our team of doctors, pharmacists, public health & medical billing experts:

    • Field names, descriptions, and normalized values are chosen by people who actually understand their meaning
    • Healthcare & life science experts add categories, search keywords, descriptions and more to each dataset
    • Both manual and automated data enrichment supported for clinical codes, providers, drugs, and geo-locations
    • The data is always kept up to date – even when the source requires manual effort to get updates
    • Support for data subscribers is provided directly by the domain experts who curated the data sets
    • Every data source’s license is manually verified to allow for royalty-free commercial use and redistribution.

    Need Help?


    About Us

    John Snow Labs , an AI and NLP for healthcare company, provides state-of-the-art software, models, and data to help healthcare and life science organizations build, deploy, and operate AI projects.

    Details

    Delivery method

    Deployed on AWS
    New

    Introducing multi-product solutions

    You can now purchase comprehensive solutions tailored to use cases and industries.

    Multi-product solutions

    Features and programs

    Financing for AWS Marketplace purchases

    AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
    Financing for AWS Marketplace purchases

    Pricing

    Anticoagulation Therapy Outcomes

     Info
    This product is available free of charge. Free subscriptions have no end date and may be canceled any time.
    Additional AWS infrastructure costs may apply. Use the AWS Pricing Calculator  to estimate your infrastructure costs.

    Vendor refund policy

    “No refunds offered. For any questions email us at info@johnsnowlabs.com 

    How can we make this page better?

    We'd like to hear your feedback and ideas on how to improve this page.
    We'd like to hear your feedback and ideas on how to improve this page.

    Legal

    Vendor terms and conditions

    Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA) .

    Content disclaimer

    Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.

    Usage information

     Info

    Delivery details

    AWS Data Exchange (ADX)

    AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.

    Additional details

    Data sets (6)

     Info

    You will receive access to the following data sets.

    Data set name
    Type
    Historical revisions
    Future revisions
    Sensitive information
    Data dictionaries
    Data samples
    Characteristics of OAC Patients With and Without Hematoma Enlargement
    All historical revisions
    All future revisions
    Chronic Care Management Differences in Anticoagulant Clinics
    All historical revisions
    All future revisions
    Chronic Care Management Patient Outcomes in Anticoagulant Regions
    All historical revisions
    All future revisions
    Participant Characteristics Anticoagulants Randomized Trial JAMA
    All historical revisions
    All future revisions
    Pulmonary Embolism Thrombolysis Treatment and Its Complications JAMA
    All historical revisions
    All future revisions
    Subgroup Analysis for Mode of Reversal Treatment FFP vs PCC
    All historical revisions
    All future revisions

    Resources

    Vendor resources

    Similar products